Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 interventional single arm study describing platelet responses and ITP remission rates in adult subjects with immune thrombocytopenia purpura receiving romiplostim

Trial Profile

A phase 2 interventional single arm study describing platelet responses and ITP remission rates in adult subjects with immune thrombocytopenia purpura receiving romiplostim

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 18 Oct 2019 According to an Amgen media release, based on the results of this trial, the U.S. FDA has approved romiplostim for an additional indication of treatment of newly diagnosed and persistent adult Idiopathic-thrombocytopenic-purpura patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
    • 31 Aug 2018 Biomarkers information updated
    • 08 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top